Baker Botts Guides Boehringer Ingelheim to FTC Clearance of Historic $13.5 Billion Asset Swap Transaction with Sanofi
As a condition of FTC clearance, the parties will divest certain pet vaccines and a cattle parasitcide product in the United States. No FTC divestitures were required in any consumer health product segments.
The Baker Botts team was led by Washington DC based partners Stephen Weissman and William Henry and associates Ryan Foley, Christine Ryu, and Matt Adler.
For more information, please see the FTC news release by clicking here.
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm of approximately 650 lawyers practicing throughout a network of offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the energy, technology, and life sciences sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.